Drug Trial Radar · NCT06442280
SGLT-2 Inhibitor and High-Dose Furosemide Plus Small-Volume Hypertonic Saline Solution in Acute HF
Last checked: Nov 19, 2026Latest source record: Jun 6, 2024 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Status unknown
Enrollment
544
Planned (sponsor's estimate)
Start
Jun 2024
Primary completion
Jan 31, 2026
Study completion Mar 30, 2026
Sponsor
- Lead sponsor
- University of PalermoAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- First posted
- Jun 4, 2024
Design
- Study type
- Interventional
- Phase
- Phase 4
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Single (participant)
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 40 years, up to 89 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of the current investigation is to demonstrate the efficacy of high-dose furosemide plus small-volume hypertonic saline solution and a Sodium-Glucose cotransporter-2 (SGLT-2) inhibitor among patients admitted for acute exacerbation of heart failure, in determining a significant increase in diuresis and natriuresis. It is also accompanied by a rapid reduction in body weight and a substantial decrease in hospitalization length without compromising renal function.
Conditions
- Heart Failure Acute
- Diabetes Type 2
- Heart Failure With Reduced Ejection Fraction
- Heart Failure With Preserved Ejection Fraction
Interventions
Dapagliflozin tabletDrug
Dapagliflozin 10 mg 1 tablet once daily
Hypertonic Saline Solution, 1 MlDrug
Intravenous infusion of furosemide combined with hypertonic saline solutions (100 mL) twice daily
Furosemide InjectionDrug
Furosemide 20 mg
Primary outcomes
What the sponsor says the trial is designed to measure.
- Diuresis from the baseline and up to 1 weekTime frame: an average of 1 week
- Natriuresis from the baseline and up to 1 weekTime frame: an average of 1 week
- Length of hospital stayTime frame: immediately after the intervention
Locations
No sites are listed on the registry yet.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.